Rituximab-based regimens for primary cardiac lymphoma: A systematic review of outcomes, challenges and future directions

Advanced Search

BPG is committed to discovery and dissemination of knowledge

Home / Archive / Volume 16, Issue 5

This Article

Academic Content and Language Evaluation of This Article

CrossCheck and Google Search of This Article

Academic Rules and Norms of This Article

Supplementary Materials of This Article

Citation of this article

Corresponding Author of This Article

Research Domain of This Article

Article-Type of This Article

Open-Access Policy of This Article

Times Cited Counts in Google of This Article

Number of Hits and Downloads for This Article

All Articles published online

Item

Count

PDF

HTML

Figures (1-1)

Tables (1-2)

Sum=22

May 24, 2025 (publication date) through May 19, 2025

Times Cited of This Article

Journal Information of This Article

Publication Name

World Journal of Clinical Oncology

ISSN

2218-4333

Publisher of This Article

Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

Systematic Reviews

World J Clin Oncol. May 24, 2025; 16(5): 104471
Published online May 24, 2025. doi: 10.5306/wjco.v16.i5.104471

Figure 1 PRISMA flow diagram of selection of studies for inclusion in the systematic review.

Citation: Bokhari SFH, Bakht D, Hasan AH, Abid MA, Amir M, Ali K, Javed MA, Khilji F, Iqbal A, Dost W. Rituximab-based regimens for primary cardiac lymphoma: A systematic review of outcomes, challenges and future directions. World J Clin Oncol 2025; 16(5): 104471
URL: https://www.wjgnet.com/2218-4333/full/v16/i5/104471.htm
DOI: https://dx.doi.org/10.5306/wjco.v16.i5.104471